Market research
RVX.TO Resverlogix Corp
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 28M
- P/E ratio
- Not available
- Analyst target
- 7.7
- Dividend yield
- Not available
- Beta
- 1.06
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA76128M1086
- Market cap
- 28M
- P/E ratio
- Not available
- Analyst target
- 7.7
- Dividend yield
- Not available
- Beta
- 1.06
About
About Resverlogix Corp
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RVX.TO discussion.
5 years, 6 months ago
Resverlogix Corp is currently in a long term downtrend where the price is trading 14.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Resverlogix Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 103.4% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 60.5% to $-2M since the same quarter in the previous year.
Based on the above factors, Resverlogix Corp gets an overall score of 2/5.